Panel Introduction

The FDA has established a formal regulatory pathway for whole-room microbial reduction devices, transforming a fragmented space into one with more straightforward rules and expectations. With hospitals still struggling to thoroughly disinfect high-touch surfaces—and many turning to UV and other adjunct tools—clarity on compliance and claims is overdue. In this section, our panel of an EVS operations leader, a hospital epidemiologist, and a former FDA infection-control chief unpacks what the new oversight means for patient safety, procurement, and the future of advanced disinfection.